Cullinan Therapeutics

Cullinan Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing a diversified pipeline of high-impact therapies for patients with cancer and autoimmune diseases. Formerly known as Cullinan Oncology, the company rebranded in April 2024 to reflect its strategic expansion into immunology, specifically leveraging its expertise in T-cell engagers to treat B-cell mediated autoimmune conditions. The company employs a 'modality-agnostic' approach, selecting the most effective therapeutic platform—whether small molecules, monoclonal antibodies, or bispecific T-cell engagers—for each specific biological target. Their business model often involves strategic partnerships, such as their high-profile collaboration with Taiho Pharmaceutical for their lead oncology asset, zipalertinib.